Directly to content
  1. Publishing |
  2. Search |
  3. Browse |
  4. Recent items rss |
  5. Open Access |
  6. Jur. Issues |
  7. DeutschClear Cookie - decide language by browser settings

Tigecycline in critically ill patients on continuous renal replacement therapy: a population pharmacokinetic study

Broeker, A. ; Wicha, S. G ; Dorn, C. ; Kratzer, A. ; Schleibinger, M. ; Kees, F. ; Heininger, Alexandra ; Kees, M. G ; Häberle, H.

In: Critical care, 22 (2018), Nr. 341. pp. 1-7. ISSN 1466-609X

[img]
Preview
PDF, English - main document
Download (794kB) | Lizenz: Creative Commons LizenzvertragTigecycline in critically ill patients on continuous renal replacement therapy: a population pharmacokinetic study by Broeker, A. ; Wicha, S. G ; Dorn, C. ; Kratzer, A. ; Schleibinger, M. ; Kees, F. ; Heininger, Alexandra ; Kees, M. G ; Häberle, H. underlies the terms of Creative Commons Attribution 4.0

Citation of documents: Please do not cite the URL that is displayed in your browser location input, instead use the DOI, URN or the persistent URL below, as we can guarantee their long-time accessibility.

Abstract

Background: Tigecycline is a vital antibiotic treatment option for infections caused by multiresistant bacteria in the intensive care unit (ICU). Acute kidney injury (AKI) is a common complication in the ICU requiring continuous renal replacement therapy (CRRT), but pharmacokinetic data for tigecycline in patients receiving CRRT are lacking.

Methods: Eleven patients mainly with intra-abdominal infections receiving either continuous veno-venous hemodialysis (CVVHD, n = 8) or hemodiafiltration (CVVHDF, n = 3) were enrolled, and plasma as well as effluent samples were collected according to a rich sampling schedule. Total and free tigecycline was determined by ultrafiltration and high-performance liquid chromatography (HPLC)-UV. Population pharmacokinetic modeling using NONMEM® 7.4 was used to determine the pharmacokinetic parameters as well as the clearance of CVVHD and CVVHDF. Pharmacokinetic/pharmacodynamic target attainment analyses were performed to explore the potential need for dose adjustments of tigecycline in CRRT.

Results: A two-compartment population pharmacokinetic (PK) model was suitable to simultaneously describe the plasma PK and effluent measurements of tigecycline. Tigecycline dialysability was high, as indicated by the high mean saturation coefficients of 0.79 and 0.90 for CVVHD and CVVHDF, respectively, and in range of the concentration-dependent unbound fraction of tigecycline (45–94%). However, the contribution of CRRT to tigecycline clearance (CL) was only moderate (CLCVVHD: 1.69 L/h, CLCVVHDF: 2.71 L/h) in comparison with CLbody (physiological part of the total clearance) of 18.3 L/h. Bilirubin was identified as a covariate on CLbody in our collective, reducing the observed interindividual variability on CLbody from 58.6% to 43.6%. The probability of target attainment under CRRT for abdominal infections was ≥ 0.88 for minimal inhibitory concentration (MIC) values ≤ 0.5 mg/L and similar to patients without AKI.

Conclusions: Despite high dialysability, dialysis clearance displayed only a minor contribution to tigecycline elimination, being in the range of renal elimination in patients without AKI. No dose adjustment of tigecycline seems necessary in CRRT.

Trial registration: EudraCT, 2012–005617-39. Registered on 7 August 2013.

Item Type: Article
Journal or Publication Title: Critical care
Volume: 22
Number: 341
Publisher: BioMed Central ; Springer
Place of Publication: London ; Berlin, Heidelberg
Date Deposited: 08 Feb 2019 11:30
Date: 2018
ISSN: 1466-609X
Page Range: pp. 1-7
Faculties / Institutes: Medizinische Fakultät Heidelberg > Department for Infectiology
Subjects: 610 Medical sciences Medicine
Uncontrolled Keywords: Tigecycline, Population pharmacokinetics, NONMEM, Dosing, Renal replacement therapy, CVVHD, CVVHDF
About | FAQ | Contact | Imprint |
OA-LogoDINI certificate 2013Logo der Open-Archives-Initiative